+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Dermatomyositis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767543
  • Report
  • 74 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Plc
  • MORE
The global clinical trial report- “2019 Dermatomyositis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Dermatomyositis. It presents in-depth analysis of Dermatomyositis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Dermatomyositis.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Dermatomyositis clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Dermatomyositis

The research work is prepared through extensive and continuous research on Dermatomyositis trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Dermatomyositis patients are identified
  • The report includes panorama of Dermatomyositis clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Dermatomyositis clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Plc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Dermatomyositis Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Dermatomyositis Clinical Trials by Region
2.2.2 Average Enrollment of Dermatomyositis Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Dermatomyositis Treatment, 2019

3. Region wise Dermatomyositis Clinical Trials
3.1 Asia Pacific Dermatomyositis Clinical Trials by Country
3.2 Europe Dermatomyositis Clinical Trials by Country
3.3 North America Dermatomyositis Clinical Trials by Country
3.4 Middle East and Africa Dermatomyositis Clinical Trials by Country
3.5 South and Central America Dermatomyositis Clinical Trials by Country

4. Dermatomyositis Clinical Trial Trends
4.1 Start Year wise Dermatomyositis Clinical Trials
4.2 Phase wise Dermatomyositis Clinical Trials
4.3 Trial Status wise Dermatomyositis Clinical Trials
4.4 Trial Type wise Dermatomyositis Clinical Trials

5. Dermatomyositis Average Enrollment Trends
5.1 Average Enrollment in Dermatomyositis Trials by Year
5.2 Average Enrollment in Dermatomyositis Trials by Phase
5.3 Average Enrollment in Dermatomyositis Trials by Status
5.4 Average Enrollment in Dermatomyositis Trials by Type of Trial

6. Companies Participating in Dermatomyositis Clinical Trials
6.1 Dermatomyositis Trials by Sponsor Type
6.2 Dermatomyositis Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Dermatomyositis Trials- Phase 1
7.2 Dermatomyositis Trials- Phase 2
7.3 Dermatomyositis Trials- Phase 3
7.4 Dermatomyositis Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Dermatomyositis Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Dermatomyositis Clinical Trials and Enrolment
Figure 5: Europe - Country wise Dermatomyositis Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Dermatomyositis Clinical Trials and Enrolment
Figure 7: North America - Country wise Dermatomyositis Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Dermatomyositis Clinical Trials and Enrolment
Figure 9: Dermatomyositis Clinical Trials by Phase
Figure 10: Dermatomyositis Clinical Trials by Trial Status
Figure 11: Dermatomyositis Clinical Trials by Type
Figure 12: Dermatomyositis Clinical Trials by Sponsor Type
Figure 13: Dermatomyositis Clinical Trials by Leading Sponsors
Figure 14: Dermatomyositis Average Enrollment by Phase
Figure 15: Dermatomyositis Average Enrollment by Trial Status
Figure 16: Dermatomyositis Average Enrollment by Type
Figure 17: Dermatomyositis- Average Enrolment by Type of Sponsors
Figure 18: Dermatomyositis- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Dermatomyositis Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Dermatomyositis Clinical Trials and Enrolment
Table 5: Europe - Country wise Dermatomyositis Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Dermatomyositis Clinical Trials and Enrolment
Table 7: North America - Country wise Dermatomyositis Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Dermatomyositis Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Dermatomyositis Average Enrollment by Phase
Table 15: Dermatomyositis Average Enrollment by Trial Status
Table 16: Dermatomyositis Average Enrollment by Type
Table 17: Dermatomyositis- Average Enrolment by Type of Sponsors
Table 18: Dermatomyositis- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Corbus Pharmaceuticals Holdings Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Plc
  • Neovacs SA
  • Novartis AG
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll